The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Coherus BioSciences Inc

Nasdaq: CHRS
Last

(U.S.) $18.83

Today's change-0.42 -2.18%
Updated April 29 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Coherus BioSciences Inc

Nasdaq: CHRS
Last

(U.S.) $18.83

Today's change-0.42 -2.18%
Updated April 29 4:00 PM -4GMT. Delayed by at least 15 minutes.

Coherus BioSciences Inc down (U.S.)$0.42

Coherus BioSciences Inc closed sharply lower Friday, dropping (U.S.)$0.42 or 2.18% to (U.S.)$18.83. Over the last five days, shares have lost 13.39% and are down 17.99% for the last year to date. This security has underperformed the S&P 500 by 14.89% during the last year.

Key company metrics

  • Open(U.S.) $19.12
  • Previous close(U.S.) $19.25
  • High(U.S.) $19.22
  • Low(U.S.) $18.40
  • Bid / Ask(U.S.) $11.12 / (U.S.) $0.00
  • YTD % change-17.99%
  • Volume211,662
  • Average volume (10-day)173,954
  • Average volume (1-month)195,167
  • Average volume (3-month)268,174
  • 52-week range(U.S.) $12.04 to (U.S.) $38.10
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$5.98
Updated April 29 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.47%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue10776
Total other revenue--------
Total revenue10776
Gross profit--------
Total cost of revenue--------
Total operating expense62786643
Selling / general / administrative111096
Research & development51685736
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-52-71-59-37
Interest income (expense), net non-operating0000
Gain (loss) on sale of assets--------
Other--------
Income before tax-53-71-59-41
Income after tax-53-71-59-41
Income tax, total--------
Net income-52-71-59-41
Total adjustments to net income--------
Net income before extra. items-52-71-59-41
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-52-71-59-41
Inc. avail. to common incl. extra. items-52-71-59-41
Diluted net income-52-71-59-41
Dilution adjustment--------
Diluted weighted average shares39383833
Diluted EPS excluding extraordinary itemsvalue per share-1.34-1.86-1.56-1.22
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.34-1.86-1.56-1.22